ArticleDrug design, development and therapy2025
Design and Evaluation of Andrographolide Analogues as SARS-CoV-2 Main Protease Inhibitors: Molecular Modeling and in vitro Studies.
Article in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Enhanced proteolytic stability and distinct mechanisms of a D-amino acid-modified antimicrobial peptide against Pseudomonas aeruginosa.Scientific reports · 2026Article
- Anti-Adipogenic Effects ofInternational journal of molecular sciences · 2026Article
- AI-Driven Plant-Derived Anti-Infectives: Integrating Traditional Wisdom into Precision Medicine Against AMR.Life (Basel, Switzerland) · 2026Review
- Andrographolide and Its Derivatives: A Comprehensive Review of Anti-Infective Properties and Clinical Potential.Molecules (Basel, Switzerland) · 2025Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The COVID-19 pandemic, caused by SARS-CoV-2, highlights the urgent need for novel antiviral agents targeting key viral proteins. The main protease (M Objective: This study aimed to design, synthesize, and evaluate C-12 dithiocarbamate andrographolide analogues as potential SARS-CoV-2 M Methods: A structure-based drug design approach was employed to design andrographolide derivatives. Molecular dynamics simulations were conducted to assess binding interactions and stability. The hit compound was synthesized and evaluated using an enzyme inhibition assay against SARS-CoV-2 M Results: Among the designed compounds, compound Conclusion: Compound
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.